Aardvark Therapeutics, Inc. (AARD) — insider trading
Health Care · Nasdaq
Aardvark Therapeutics, Inc. (AARD) has 18 reported SEC Form 4 insider transactions in our data, including 8 open-market purchases among the most recent 18 (latest 2026-02-09).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-02-09 | Lee Tien-Li | Director, Officer (Chief Executive Officer), 10% owner | Grant / award / vesting (derivative) | 203,851 | $0.00 | $0 | Form 4 |
| 2026-02-09 | Jaiman Manasi | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 70,549 | $0.00 | $0 | Form 4 |
| 2026-02-09 | Sun Nelson | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 70,549 | $0.00 | $0 | Form 4 |
| 2025-12-11 | Lee Tien-Li | Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | 7,000 | $14.49 | $101.4K | Form 4 |
| 2025-12-11 | Sun Nelson | Officer (Chief Financial Officer) | Open-market purchase | 3,000 | $14.40 | $43.2K | Form 4 |
| 2025-10-15 | Jones Bryan | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 1,250 | $0.00 | $0 | Form 4 |
| 2025-10-15 | Jones Bryan | Officer (Chief Operating Officer) | Option exercise / conversion | 1,250 | $4.24 | $5.3K | Form 4 |
| 2025-10-15 | Lee Tien-Li | Director, Officer (Chief Executive Officer), 10% owner | Option exercise / conversion (derivative) | 1,229 | $0.00 | $0 | Form 4 |
| 2025-10-15 | Lee Tien-Li | Director, Officer (Chief Executive Officer), 10% owner | Option exercise / conversion | 1,229 | $4.24 | $5.2K | Form 4 |
| 2025-09-15 | Lee Tien-Li | Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | 3,500 | $9.94 | $34.8K | Form 4 |
| 2025-09-15 | Lee Tien-Li | Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | 6,500 | $9.51 | $61.8K | Form 4 |
| 2025-09-12 | Lee Tien-Li | Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | 5,000 | $8.50 | $42.5K | Form 4 |
| 2025-09-11 | Lee Tien-Li | Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | 6,000 | $7.82 | $46.9K | Form 4 |
| 2025-09-10 | Lee Tien-Li | Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | 9,000 | $7.91 | $71.2K | Form 4 |
| 2025-09-09 | Sun Nelson | Officer (Chief Financial Officer) | Open-market purchase | 6,000 | $8.07 | $48.4K | Form 4 |
| 2025-08-28 | Lee Tien-Li | Director, Officer (Chief Executive Officer), 10% owner | Option exercise / conversion (derivative) | 17,209 | $0.00 | $0 | Form 4 |
| 2025-08-28 | Lee Tien-Li | Director, Officer (Chief Executive Officer), 10% owner | Option exercise / conversion | 17,209 | $4.24 | $73.0K | Form 4 |
| 2025-06-11 | Lee Tien-Li | Director, Officer (Chief Executive Officer), 10% owner | Grant / award / vesting (derivative) | 549,534 | $0.00 | $0 | Form 4 |
Ask the chat about AARD's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Aardvark Therapeutics, Inc. (AARD).
Last updated 2026-02-09 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.